<DOC>
	<DOCNO>NCT01955876</DOCNO>
	<brief_summary>This study regulatory post-marketing surveillance Japan , And local prospective observational study patient receive Fosrenol . The objective research collect information safety Fosrenol launching , mean collect information adverse event , especially adverse event digestive system include constipation serious adverse event , adverse drug reaction drug administer below-mentioned target patient six month . The secondary objective collect information safety drug administer six month , mean collect information safety drug administer 12 month target patient already treat drug six month . And also time 12 month administration Lanthanum carbonate dialysis conduct , extend ' administration continue conduction dialysis , Sept. 30 , 2015 . The efficacy fosrenol evaluate observe serum P ( phosphorus ) level serum PTH ( parathyroid hormone ) level change .</brief_summary>
	<brief_title>Fosrenol Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients investigator decide treat Lanthanum carbonate first time respective medical institution . Those medical institution understand objective investigation conclude write contract Bayer Yakuhin . The decision treat patient Lanthanum carbonate make independently investigator prior study inclusion . Patients treat Lanthanum carbonate indication `` Hyperphosphatemia '' chronic kidney disease dialysis '' . Patients contraindicate base product label . Patients already treat Fosrenol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Fosrenol</keyword>
	<keyword>hyperphosphatemia</keyword>
	<keyword>chronic kidney disease dialysis</keyword>
</DOC>